ONECYTE BIOTECHNOLOGIES, INC.
Biotech · Private
Single-cell proteomics platform for rapid high-performing cell-line selection in biologics manufacturing
- Grants
- $5.1M
- 6 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 4
- 0 granted · 4 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2018201920202021202220232024
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | National Science Foundation · Phase I · SBIR Phase I: A High Throughput Microfluidics Platform to Measure Secretion from Single Cells | $225,000 | |
| Federal grant | National Science Foundation · Phase I · SBIR Phase I: A high throughput microfluidic platform to accelerate biomanufacturing transitions in the COVID-19 response | $256,000 | |
| Federal grant | Department of Health and Human Services · Phase II · A proprietary single-cell analytics platform for accelerating biologics manufacturing | $855,264 | |
| Federal grant | Department of Health and Human Services · Phase II · A proprietary single-cell analytics platform for accelerating biologics manufacturing | $1,710,528 | |
| Federal grant | Department of Health and Human Services · Phase II · A proprietary single-cell analytics platform for accelerating biologics manufacturing | $855,264 | |
| Federal grant | National Science Foundation · Phase II · SBIR Phase II:A high throughput microfluidic platform to accelerate biomanufacturing transitions in biologics development | $1,186,726 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1693 | AEON RESPIRE, INC. | — | — |
| 1694 | NEMUCORE MEDICAL INNOVATIONS, INC. | — | — |
| 1695 | Epigen Biosciences, Inc. | — | — |
| 1696 | ONECYTE BIOTECHNOLOGIES, INC. | — | — |
| 1697 | Igenica | — | — |
| 1698 | ZabBio, Inc. | — | — |
| 1699 | EVOQ THERAPEUTICS, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Systems And Methods For High-throughput Cell Line Developmentapplication
- Systems And Methods For High-throughput Cell Line Developmentapplication
- Systems And Methods For High-throughput Cell Line Developmentapplication
- Systems And Methods For High-throughput Cell Line Developmentapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.